Psychopharmacology Archives - Psych Scene Hub

May 11, 2023

Time to read: 2 minutes

REXULTI® (brexpiprazole) FDA Approved for Treating Agitation in Alzheimer’s Disease Patients: A New Breakthrough in Neuropsychiatric Symptom Management
Otsuka Pharmaceutical and Lundbeck LLC have ...
READ MORE
Dr Sanil Rege
April 17, 2023

Time to read: 13–15 minutes

Revisiting Tricyclic Antidepressants: Understanding the Differences and Advantages for Effective Depression Treatment
While newer antidepressant medications have gained popularity in recent years, tricyclic antidepressants (TCAs) remain an essential treatment option for...
READ MORE
Dr Sanil Rege
March 21, 2023

Time to read: 2 minutes

Xanomeline-Trospium (KarXT) Shows Significant Reductions in Symptoms of Schizophrenia in Phase 3 Trial – Targeting the Muscarinic Receptors
...
READ MORE
Dr Sanil Rege
March 14, 2023

Time to read: 9 minutes

Targeting Muscarinic Acetylcholine Receptors In Schizophrenia: The Latest Research
For decades, researchers have been investigating the role of muscarinic acetylcholine receptors (mAChRs) in the development an...
READ MORE
March 9, 2023

Time to read: 1 minutes

Changes to the Classification of Psilocybin and MDMA to Enable Prescribing by Authorised Psychiatrists
Treatment options for mental health conditions resistant to treatment are currently limited. ...
READ MORE
February 2, 2023

Time to read: 1 minutes

Zuranolone Improved Depression, Anxiety and Insomnia in Postpartum Depression
Zuranolone is a neurosteroid developed in the treatment of postpartum depression. Neurosteroids or Neuroactive Steroids (NAS) are endogenous ster...
READ MORE
Dr Sanil Rege
January 21, 2023

Time to read: 8 minutes

Varenicline (CHAMPIX) – Mechanism of Action | Psychopharmacology | Clinical Application
Varenicline (CHANTIX /CHAMPIX) is a nicotinic acetylcholine receptor (nAChR) partial agonist indicated as a smoking cessation drug. ...
READ MORE
December 19, 2022

Time to read: 1 minutes

Cariprazine Approved by FDA as Adjunctive Treatment for Major Depressive Disorder
AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR® (cariprazine) ; (known as Reagila in Australia) as an adjunctiv...
READ MORE
Dr Sanil Rege
November 24, 2022

Time to read: 34–41 minutes

Primer on Neurobiology and Neuropsychiatry of Sleep – Application to Clinical Practice
Humans spend 1/3rd of their life sleeping. Sleep is critical to adaptive human functioning with its links to cognition, mood, ...
READ MORE
Dr Sanil Rege
October 27, 2022

Time to read: 10 minutes

Memantine – Mechanism of Action | Psychopharmacology | Clinical Application
Memantine is a low-affinity voltage-dependent non-competitive NMDA receptor antagonist that is approved for treating moderate-...
READ MORE